Olmesartán/Hidroclorotiazida Tarbis (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartán/Hidroclorotiazida Tarbis, is an angiotensin II receptor blocker combined with a thiazide diuretic presented as a tablet for oral use. It treats essential hypertension in adult patients, often when monotherapy is insufficient. GNH USA supplies Olmesartán/Hidroclorotiazida Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/hydrochlorothiazide is used to manage hypertension by blocking the renin‑angiotensin system and promoting diuresis. Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. Uncontrolled blood pressure on monotherapy: provides additional blood‑pressure reduction when a single agent is inadequate. High‑risk cardiovascular patients: helps achieve target blood pressure in individuals with additional cardiovascular risk factors.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urinary frequency - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset (nausea, abdominal discomfort)

Serious or Rare Side Effects: - Severe hypotension - Acute renal impairment or failure - Hyperkalemia - Angioedema (swelling of face, lips, tongue) - Pancreatitis - Severe allergic reactions (rash, Stevens‑Johnson syndrome)

Before initiating therapy, consider the following precautions: - Monitor blood pressure: check regularly to ensure therapeutic response. - Assess renal function: obtain baseline creatinine and eGFR, repeat as needed. - Check electrolytes: especially potassium and sodium levels during treatment. - Avoid in severe hepatic impairment: use only if benefits outweigh risks. - Contraindicated in pregnancy: do not use during gestation. - Use caution in elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep in the original pack, protect from moisture.

Olmesartan/hydrochlorothiazide may interact with several medicines. Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering; monitor for excessive hypotension. - Antidiabetic agents: may enhance glucose‑lowering effect; adjust diabetes medication as needed.